INTRODUCTION
The cornea is like a watch glass on the external surface of the eye, and its optical clarity is essential for vision. When the cornea is injured or inflamed, normally quiescent cells of the corneal stroma, the keratocytes, transform into fibroblasts to repair the damage by secreting scar tissue (1, 2) . The presence of fibrotic extracellular matrix (ECM) components in stromal scars results in scatter of incident light, causing a deterioration of visual function (3, 4) . Visual impairment and blindness owing to corneal scarring affect millions worldwide (5, 6) and is the commonest indication for corneal transplantation (penetrating keratoplasty) in the developing world (7) . Penetrating keratoplasty is the most widespread organ grafting procedure and usually highly effective in improving vision (8) ; however, global demand for donor corneal tissue vastly exceeds its availability. Moreover, postoperative complications, particularly immune rejection, reduce the functional survival time for corneal allografts (9) , especially in developing countries (10) . For these reasons, there is increasing interest in the development of therapeutic alternatives to corneal transplantation, including stem cell therapy, cell-free collagen scaffolds, bioengineered constructs, and corneal prostheses (11) (12) (13) (14) .
The discovery of multipotent stem cells in the corneal stroma (15, 16) has opened up the possibility of developing a cell-based approach to treating blinding corneal stromal disorders. In a mouse model of corneal opacity, human stromal stem cells were effective in regenerating normal corneal ECM and repairing collagen fibril defects (17) . The ability of mesenchymal stem cells to restore corneal transparency in lumican knockout mice was subsequently confirmed with umbilical cord stem cells (18) . The presence of adult stem cells of mesenchymal lineage in human corneal stroma has been the subject of several reports (13, (19) (20) (21) . Mesenchymal stem cells are immune-suppressant and therefore may have a role not only in remodeling but also in preventing inflammation, scarring, and immune rejection of transplanted tissue (22, 23) .
The transitional region between optically clear cornea and opaque sclera, known as limbus, is the location of a population of epithelial stem cells that can be obtained by biopsy and expanded in vitro. Limbal epithelial cells, obtained from surface biopsy, have been used successfully for autologous treatment of limbal stem cell deficiency in clinical trials (24) (25) (26) (27) (28) . Cultures from limbal biopsy procedures also contain a population of mesenchymal cells with properties similar to mesenchymal stem cells from bone marrow (21) . Other studies also have identified mesenchymal stem cells in the limbal region of the corneal stroma (19) (20) (21) (22) . We have proposed that these reports all describe a single population of cells, the corneal stromal stem cells we have shown to differentiate to keratocytes and to regenerate stromal tissue in vivo (13) . The implication that corneal stromal stem cells may be present in biopsy samples suggests their availability for autologous use.
Our current study addresses the hypothesis that mesenchymal cells obtained from limbal biopsy tissue from human corneas can be expanded in a culture medium containing autologous serum and can differentiate to keratocytes with the potential for use in cell-based therapy. To demonstrate this property, we used a therapeutic model in which human limbal biopsy-derived stromal cells (LBSCs) embedded in fibrin gel were applied to the surface of a healing murine debridement wound. We report that human stromal cells derived from limbal biopsies can not only differentiate to functional keratocytes in vitro but also induce regeneration of damaged stromal tissue in vivo, resulting in a matrix indistinguishable from that of native cornea.
RESULTS
Stromal cells can be obtained from limbal biopsies Cells were obtained from donated human corneas from which a central button had been taken for penetrating keratoplasty. Tissue samples were excised in a manner simulating limbal biopsies used to obtain epithelial cells from living human patients ( fig. S1) (24, 25, 29, 30) . In initial trials, stromal cells were released by collagenase digestion with or without prior removal of epithelial cells, using the neutral protease dispase. Previously, we found that an initial dispase treatment yielded mesenchymal cell cultures free of epithelial cells (15) . Isolation of cells using only collagenase (omitting dispase) produced primary cultures (P0) cells with both epithelial and mesenchymal morphologies (Fig. 1A) . After expansion (P3), cells with epithelial morphology were lost, and cultures consisted of homogeneous small mesenchymal cells (Fig. 1A) . Collagenase-only isolation of cells resulted in significantly faster proliferation of LBSC than dispase/collagenase isolation (Fig. 1B and  table S1 ).
LBSCs exhibit stem cell-like properties Mesenchymal cells isolated from limbal biopsies were highly clonogenic irrespective of the culture conditions (Fig. 1C) . About 40% of P3 cells grew as colonies from cells expanded in the presence of fetal bovine serum (FBS) or human serum (HS) (Fig. 1D and table S2 ). Cells cultured in FBS had significantly smaller colonies compared to clones in HS (Fig. 1E  and table S3 ). Stromal fibroblasts, mesenchymal cells from central cornea, did not form colonies under identical conditions (Fig. 1F) . When cultured under substratum-free conditions, LBSCs organized into freefloating spheres ( fig. S2A ). Under these conditions, LBSCs up-regulated expression of genes associated with both adult and pluripotent stem cells (ABCG2, Nestin, OCT4, PAX6, NGFR, and SOX2) ( fig. S2B ).
LBSCs differentiate into keratocytes in vitro
LBSCs cultured on a collagen gel substratum in ascorbate-containing, serum-free keratocyte differentiation medium (KDM) exhibited a marked decrease in the expression of the stem cell genes ABCG2 and Nestin and an increase in expression of the following genes associated with keratocyte differentiation: ALDH3A1, AQP1, KERA, and PTGDS ( Fig. 2 ) (16, 31, 32) . When LBSCs were cultured on a substratum of parallel, aligned nanofibers (14, 33) in KDM, the cells secreted a thick ECM of fibrillar collagen type I and keratan sulfate-containing proteoglycans (Fig. 3) . The cells and collagen fibrils showed strong alignment with the nanofiber substratum, but collagen deposited 30 to 40 mm above the substratum exhibited an orientation rotated by about 40°with respect to the lower layers ( Fig. 3A and movie S1 ). This rotation is similar to that of stromal lamellae in vivo, demonstrating a lamellar organization similar to that of corneal stroma. After 30 days in culture, the collagen construct was 35 to 40 mm in thickness (Fig. 3B) , a value independent of the culture medium. Conditioned media pooled from cultures contained high molecular weight (>130 kD) keratan sulfate-containing proteoglycans, unique components of corneal ECM (Fig. 3C ).
Human LBSCs engraft in murine cornea in vivo
The ability of LBSCs to prevent and/or remediate corneal scarring was examined with a mouse corneal debridement model, which induces fibrotic matrix deposition and long-term disruption of the organization of the stromal collagenous ECM structure and produces visible stromal scars (23) . At the time of wounding, 50,000 LBSCs were applied to the wound bed in a solution of fibrinogen, which gelled in response to thrombin ( fig. S3 ). At 1 week after wounding, 3,3′-dioctadecyloxacarbocyanine (DiO)-labeled LBSCs remained in the cornea distributed throughout the wounded area ( Fig. 4A and fig. S4 ). LBSCs remained in the anterior stroma for at least 4 weeks, during which time the average number of engrafted cells decreased by about half ( fig. S4 ). During that time, no inflammation or rejection was observed in response to these cells. Four weeks after wounding, anterior stromal tissue subjacent to the corneal epithelium and near engrafted LBSCs contained human keratocan and type I collagen, components of normal transparent stromal ECM (Fig. 4B) .
LBSCs promote regeneration of native stromal tissue during wound repair Wound repair in the corneal stroma typically results in the accumulation of a number of ECM components associated with light-scattering scar tissue, absent in normal stroma, including fibronectin, tenascin C, biglycan, hyaluronan, type III collagen, and SPARC (secreted protein acidic and rich in cysteine) (1, (34) (35) (36) (37) (38) . In wounds allowed to heal without addition of LBSC (Fig. 5A, left panels) , fibrotic markers hyaluronan, fibronectin, tenascin C, biglycan, and decorin were abundant in anterior stroma, indicating scar formation. In wounded corneas treated with LBSCs, only the proteoglycan decorin, a component of normal stromal matrix, was detected (Fig. 5A) . Similarly, mRNAs for mouse type III collagen and SPARC were up-regulated 2 weeks after wounding in debrided corneas; however, the presence of LBSCs significantly reduced the upregulation to levels similar to unwounded controls (Fig. 5B) .
Low-magnification photos of wounded corneas with diffuse lighting revealed the presence of visible scarring in all eyes that healed without LBSCs, whereas visible scars were absent in all eyes receiving LBSCs (Fig. 6A) . Light scatter by corneal scars, a cause of reduced visual acuity, was assessed using spectral-domain optical coherence tomography (OCT). As shown in Fig. 6B , scatter in individual cross-sectional OCT scans was revealed as bright stromal regions in untreated corneas 2 and 4 weeks after debridement. Thresholding of these bright pixels in en face projections allowed a qualitative assessment of scar area and volume (Fig. 6C) . Quantification of the thresholded images revealed a significant increase in light scatter in the untreated scars at both 2 and 4 weeks after wounding (Fig. 6D) . In eyes treated with LBSCs at the time of wounding, however, light scatter was not increased compared to the preoperative normal corneas (Fig. 6D ). Statistical analyses of the OCT data are presented in table S4.
Corneal transparency relies on a high level of ultrastructural organization of the collagenous ECM of the stroma (39, 40) . It was therefore important to assess whether LBSC-treated eyes showed differences in collagen organization compared to wounds that did not receive stem cells. Transmission electron micrography of the healed untreated wounds showed the ablated region of the anterior stroma to be reconstituted with ECM typical of that of corneal scars (Fig. 6E , left panel). New ECM lacked characteristic lamellae organization. Collagen fibrils were large (inset) and typically not tightly packed or in parallel orientation, and the tissue contained amorphous deposits and empty regions known as lakes (41) . In healed corneas treated with LBSCs, collagen organization in the stroma was essentially indistinguishable from that of native tissue (Fig. 6E) . Collagen was organized into distinct layers (lamellae) containing small, uniform, tightly packed fibrils. Keratocyte processes were seen sandwiched between lamellae. Epithelial cells had elaborated a continuous basement membrane. Higher magnification of the fibrils (Fig. 6E , insets) showed fibril diameters in LBSC-treated tissue to be significantly smaller than those of the untreated scars [31.0 ± 2.9 nm versus 50.6 ± 6.6 nm, respectively (n = 28); P = 0.001, single-sample t test].
LBSC treatment reduced corneal vascularization in mice
Adult cornea is a nonvascularized tissue, and neovascularization in response to inflammation or trauma can represent a threat to vision. Immunostaining of healed corneas for CD31, a marker of vascular endothelial cells, revealed blood vessels in the central region of all (five of five) corneas that healed without addition of LBSCs (Fig. 7A) . Conversely, three of five corneas that healed with LBSC treatment were free of central blood vessels (Fig. 7B) . c 2 analysis of these results demonstrated a significant reduction in the vascularization in response to LBSC treatment (Fig. 7C) .
DISCUSSION
Over the past decade, we have characterized multipotent mesenchymal stem cells in human corneal stroma that differentiate to keratocytes and elaborate a multilamellar collagenous ECM resembling that of cornea stroma (14-17, 31, 33) . In vivo, these cells restore transparency to lumican knockout mice, which have hazy stromas and disorganized stromal collagen (17) . The current study reveals two new properties of these cells. First, these cells can be obtained in a biopsy procedure that will permit autologous use. Second, we show that in an actively healing wound, these cells suppress accumulation of fibrotic scar tissue and promote regeneration of new native, transparent corneal ECM. Together, these findings present an argument for investigating clinical use of LBSCs to treat corneal scarring.
Our data demonstrate that corneal stromal stem cells can be obtained from a small surface ocular biopsy. In the current study, we emulated a biopsy procedure, but clinical use of such biopsies to obtain limbal epithelial stem cells is well established (24, 25, 29) . The presence of mesenchymal cells in limbal biopsy tissue has been described (21) . The current study confirms that mesenchymal stem cells obtained from limbal biopsies are functionally equivalent to corneal stromal stem cells we have previously described, on the basis of sphereforming ability ( fig. S2 ), gene expression patterns (Fig. 2) , and the ability to organize stromal ECM in vitro (Fig. 3) . The importance of this finding is that we are now able to use a clinically established procedure to obtain autologous stem cells with regenerative potential. These cells also grow rapidly in HS, thus allowing production of a fully autologous, xenobiotic-free cell-based reagent.
Recent reports have described mesenchymal stromal cells proximal to the epithelial basement membrane in limbal regions near epithelial stem cells. These mesenchymal "niche cells" are thought to help maintain the phenotype of limbal epithelial stem cells in vivo (42) (43) (44) . Niche cells can form spheres in vitro and express stem cell genes, including ABCG2, SOX2, Nanog, OCT4, and Nestin (20, 43, 45, 46) . LBSCs isolated in this study from human limbal biopsies closely resembled niche cells. They grew more rapidly when only collagenase was used in their isolation, and they were highly clonogenic, formed spheres, and expressed genes characteristic of both adult and pluripotent cells. By these criteria, LBSCs, corneal stromal stem cells, and limbal niche cells appear indistinguishable and probably represent the same population of neural crest-derived mesenchymal stem cells.
An important advance contributed by this study is observation that LBSCs induce deposition of a native stromal tissue rather than scar tissue in healing wounds. Previous in vivo studies have used lumicannull mice, which develop stromal haze owing to abnormal collagen fibrillogenesis (17, 18) . Although the disruption of stromal matrix in these mice resembles that in scars, it is not evident that restoration of transparency to lumican-null corneas is fully analogous to remediation of corneal scars. In the current study, we found that human LBSCs in the healing wound allowed regeneration of a fully transparent native stromal tissue. The new tissue had no expression of fibrotic mRNA or proteins, had no change in light scatter, and had highly organized stromal ECM indistinguishable from that of normal mouse cornea. Few mammalian tissues heal by regenerating native tissue. Scarring provides a strong and rapid structural repair, but tissue functionality can be impaired by scar tissue. This is particularly true for cornea in which collagen fibril diameter, parallel alignment, packing, and lamellar organization are essential for vision. Traumatic damage to stroma typically heals, leaving scar tissue with disorganized collagen that scatters light and produces long-term disruption of vision. The ability of LBSCs to induce the replacement of ablated tissue with transparent ECM containing native components with collagen organization indistinguishable from that of normal stroma is an exciting finding that points to the clear potential for use of these cells in clinical applications to treat human corneal scars.
Here, LBSCs were engrafted only in the most anterior portion of the stroma and were in low abundance in comparison to the mouse stromal cells. Amelioration of fibrotic matrix, light scatter, and disruption of the stromal organization occurred both where LBSCs were located and in more posterior regions of the stoma. The lack of colocalization of LBSCs and scarring suggests that LBSCs exert their effects indirectly. Rather than simply replacing mouse stromal ECM with that produced by the differentiated LBSC, these cells are likely exerting a paracrine influence on the mouse stromal cells repopulating the wounded region. The mechanism of this regenerative effect is unknown. The ability of the stem cells to work at a distance may be an advantage in cell-based therapy of existing scars, in that it may not be necessary to saturate scar tissue with stem cells but rather only to deliver them proximal to the region needing to be regenerated. Whether existing scars can be treated with these cells remains an open question.
Much work over the previous decade has focused on corneal limbal epithelial stem cells for treatment of limbal stem cell deficiency, a potentially blinding but rare condition. Autologous limbal epithelial stem cells have been successfully used to correct this condition in several human trials (24) (25) (26) (27) (28) 47) . Corneal epithelium and stroma are structurally and functionally distinct tissues, and epithelial stem cells are not suitable for stromal therapy. However, the positive results of pioneering clinical trials with epithelial stem cells and the data presented in our current study strongly support the idea that autologous mesenchymal stem cells (the LBSCs) may be successful in treating stromal scarring, the major cause of corneal blindness in the world. Because these cells can be obtained and cultured in an autologous, xenobioticfree fashion and because fibrinogen-based adhesives are currently approved for ocular applications, barriers to bringing this treatment to clinical trial may be modest.
In summary, we have found a population of mesenchymal cells expanded from human limbal biopsy tissue with the potential to differentiate into keratocytes, to generate stromal tissue in vitro, to block corneal scarring, and to stimulate regeneration of transparent stromal tissue in murine healing wounds in vivo. The ability to obtain cells from clinically reliable biopsies and to expand them in HS presents the opportunity to use these cells clinically to remediate cornea wounds and scars.
MATERIALS AND METHODS

Study design
The purpose of this study was to determine if mesenchymal cells present in human corneal limbal biopsies (LBSCs) differentiate into corneal keratocytes in vitro and whether they can prevent corneal scarring in a murine model in vivo. In vitro, stem cell potential was assessed using clonogenic potential, sphere formation, and expression of stem cell genes. Keratocyte differentiation was examined by gene and protein expressions and by secretion of typical stromal ECM. In vivo, LBSCs were introduced into mouse corneal debridement wounds, and the effect on corneal transparency, fibrotic ECM expression, and ECM ultrastructural organization was assessed. Statistical analyses used two-sided t tests and two-way ANOVA. In vivo experiments were designed to provide a power of 0.8 on the basis of results from our previous study (23) with animals randomized as to treatment. Collection and analysis of in vivo data were carried out with observers masked as to treatment groups. No adverse events were observed, and no data points were excluded from analyses.
Limbal biopsy
Human corneo-scleral rims from donors younger than 60 years with less than 5 days of preservation were obtained from the Center for Organ Recovery and Education (www.core.org). Rims were rinsed twice in Dulbecco's modified Eagle's medium (DMEM/F12) containing gentamicin, penicillin, and streptomycin for 10 min each. As illustrated in fig. S1 , under a dissecting microscope, residual conjunctiva was grasped with a toothed forceps, and subconjunctival dissection was carried out with Vannas scissors toward the anatomical limbus extending 0.5 mm into the clear cornea. Conjunctiva was excised, and dissection of anterior limbal tissue was carried out circumferentially in the same plane. An annular ring of tissue consisting of the superficial limbal epithelium and stroma with 0.5 mm of cornea and sclera on either side was excised. This was divided into equal halves, and each half was further divided into four equal segments (total of eight segments)~4.5 mm each.
Isolation and culture of stromal cells Four limbal segments were incubated in collagenase (0.5 mg/ml) (Sigma-Aldrich, type L) overnight at 37°C, without epithelial removal. The remaining four segments were first incubated for 40 min in Dispase II neutral protease (Zen-Bio) at 37°C. Epithelial cells were removed by gentle scraping, and the stripped limbal segments were incubated in collagenase similar to the first four segments. The digests were ticturated, incubated for an additional hour, and filtered through a 70-mm nylon screen to obtain a singlecell suspension. Cells obtained from each segment were seeded onto FNC (AthenaES)-coated wells of a 12-well tissue culture plate in stem cell growth medium (17) containing 2% (v/v) FBS or pooled HS (Innovative Research). Culture media were changed every other day, and cells were subcultured by brief digestion with TrypLE Express (Life Technologies) when 90% confluent into six-well plates, 25-cm 2 T-flasks, and 175-cm 2 T-flasks at P1, P2, and P3, respectively. Corneal fibroblasts were isolated by collagenase digestion of the peripheral 1-to 2-mm corneal rim left behind after excising the limbus and the sclera and expanded in DMEM/F12 with 10% FBS and used at P4 to P6 (15) .
Clonogenic assay (fibroblast colony-forming units) P3 cells were plated at a density of 250 cells in a 10-cm diameter dish (~5 cells/cm 2 ) in the same media that were originally used to culture the cells. After 10 days, media were removed, and cells were fixed with cold methanol for 10 min and then stained with 0.1% crystal violet in 20% ethanol for 5 min. Colonies of >50 cells were evaluated as to size and number with Fiji (ImageJ) software. Colony counts were determined in duplicate for cell lines derived from four donor corneas (n = 8). Diameter of colonies in four dishes was determined for each condition (n > 400).
Sphere formation P3 LBSCs were placed in six-well plates coated with poly(2-hydroxyethyl methacrylate) (polyHEMA) (48) at a density of 3000 cells per well in sphere medium [Advanced DMEM (containing GlutaMAX, Gibco, 12491), B27 (1:50), basic fibroblast growth factor (10 ng/ml), epidermal growth factor (20 ng/ml), gentamicin (50 mg/ml), streptomycin (100 mg/ml), and penicillin (100 IU/ml)]. The individual spheres were photographed and collected for RNA analysis on day 7.
Differentiation to keratocytes P3 LBSCs were cultured on collagen gel-coated 12-well plates at a density of 100,000 cells per well. After 24 hours, medium was changed to KDM consisting of Advanced DMEM (containing GlutaMAX, Gibco, 12491), ascorbate-2-phosphate (1 mM), fibroblast growth factor-2 (10 ng/ml), and transforming growth factor-b3 (0.1 ng/ml) (14) . One week later, the gel was digested with 0.5 ml of collagenase (2 mg/ml, Sigma-Aldrich, type L). Cells were collected by centrifugation and lysed in RLT buffer (Qiagen) for RNA isolation.
Gene expression before and after differentiation RNA isolated by Qiagen Miniprep was transcribed into complementary DNA with SuperScript III (Life Technologies) and analyzed for expression of stem cell (ABCG2 and Nestin) and keratocyte (ALDH, AQPR1, CHST6, Keratocan, and PTGDS) gene markers with procedures and primers described previously (16, 17, 31) . Assessment of mRNA copy numbers was carried out using standard curves based on linearized plasmids containing the amplified sequences (31) .
Production of stromal matrix P3 cells were plated on 15-mm-diameter poly(e-caprolactone) aligned nanofiber inserts (Nanofiber Solutions, no. 242402) in a 24-well plate at a density of 20,000 cells per well. After 24 hours in stem cell growth medium, cultures were shifted to KDM. The medium was changed every 3 days for 1 month, after which the tissue was fixed in paraformaldehyde and immunostained (as below) for collagen I, for F-actin with phalloidin, and for nuclear DNA with DAPI (14, 33) . Stained constructs were imaged with an Olympus FluoView 1000 confocal microscope with a 20× oil immersion objective. Z-stack images captured optical sections throughout the construct and were used to determine construct thickness. Proteoglycans isolated from the culture medium were separated by polyacrylamide gel electrophoresis and detected by immunoblotting with antibody J19 to detect keratan sulfate, as described previously (14) . Briefly, 7-week-old female C57BL/6 mice in randomized groups of 6 to 10 were anesthetized by intraperitoneal injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). Our previous study and power analysis determined that at least six eyes were required for statistical significance in OCT analysis and that 2 and 4 weeks provided appropriate time points for analysis of gene expression and fibrosis (23) . One drop of proparacaine hydrochloride (0.5%) was added to each eye before debridement. Corneal epithelial debridement was performed by passing an AlgerBrush II (The Alger Company) over the central 2 mm of the mouse cornea. Once the epithelium was removed, a second application of the AlgerBrush II was used, this time applying more pressure to remove the basement membrane and 10 to 15 mm of anterior stromal tissue. See fig. S3 for a schematic of this procedure. Immediately after the procedure, mice received ketoprofen (3 mg/kg) for analgesia.
Fibrin gel and LBSC application
LBSCs expanded in HS at 1 × 10 6 cells/ml in DMEM/F-12 were stained with Vybrant DiO (50 mg/ml) (Life Technologies) for 20 min at 37°C. The cells were washed twice with DMEM/F-12 and resuspended in a solution of human fibrinogen, 20 mg/ml in PBS at 2.5 × 10 7 cells/ml. This concentration was determined to be the maximum number of cells that was retained on the corneal surface during healing. The relationship between cell number and biological efficacy was not investigated. After wounding, 0.5 ml of thrombin (100 U/ml, Sigma) was added to the wound bed, followed immediately by 1 ml of fibrinogen (with or without LBSCs). After 1 to 2 min, the fibrinogen had gelled, and a second round of thrombin and fibrinogen was added. The wound was irrigated with sterile PBS, and a drop of gentamicin ophthalmic solution (0.3%) was added. The corneal epithelium closed the wound in 24 to 36 hours. Immunostaining was performed after 4 weeks, as described above. Eyes were examined daily for signs of rejection and infection for 1 week and weekly thereafter.
Optical coherence tomography OCT was performed weekly to quantify light scatter, the cause of reduced vision in corneal scars (3, 4) . Mice were anesthetized by intraperitoneal injection of ketamine (50 mg/kg) and xylazine (5 mg/kg), and eyes were scanned with a Bioptigen SDOCT (Bioptigen). Animals were randomized as to order of analysis, and scanning data were collected and analyzed in a masked fashion regarding experimental treatment of the animals. Image processing and analysis were conducted with ImageJ [National Institutes of Health (NIH)] and MetaMorph 7.7.3 (Molecular Devices Inc.). For quantification of corneal light scatter, Imaris (Bitplane USA) was used to isolate the cornea from the lens, iris, and interfering eyelashes. Pixel intensity measurements were taken both of the cornea and of the background with ImageJ and exported to Excel (Microsoft Corp.), where the average background pixel intensity was subtracted from the average corneal pixel intensity. For generating threshold images, corneal epithelium was removed with MetaMorph to isolate only the corneal stroma. Control eyes were used to set the threshold, and scar volume beyond the control threshold was displayed graphically.
Transmission electron microscopy Three corneas per group were analyzed by transmission electron microscopy. The corneas were processed as described previously (17, 23) . Briefly, tissue was fixed immediately postmortem in fresh 4% paraformaldehyde, 2.5% glutaraldehyde, 0.1 M sodium cacodylate (pH 7.4), and 8 mM CaCl 2 , followed by postfixation with 1% osmium tetraoxide. After dehydration in an ethanol series followed by propylene oxide, corneas were infiltrated and embedded in a mixture of EMbed 812, Nadic methyl anhydride, dodecenyl succinic anhydride, and DMP-30 [2,4,6-tri(dimethylaminomethyl) phenol] (Electron Microscopy Sciences). Thin sections were cut with a Leica Ultracut UCT ultramicrotome equipped with a diamond knife and were stained with 2% aqueous uranyl acetate and 1% phosphotungstic acid (pH 3.2). Anterior and posterior stroma regions of sections from central cornea were captured by investigators masked to the experimental treatment of the eyes. Micrographs were captured at 80 kV with a JEOL-1400 transmission electron microscope (JEOL Ltd.) equipped with a Gatan Orius wide-field side mount charge-coupled digital camera (Gatan Inc.). LBSCtreated eyes were fully sectioned and serially screened to confirm the absence of scarring.
Statistical analyses
LBSCs were isolated from four separate donor eyes, so data in Figs. 1, 2, 3, and 6 and fig. S2 present mean values of four biological replicates. P values for differences were determined by double-sided nonparametric t tests or ANOVA with Tukey's post hoc analysis, as indicated in figure captions, with GraphPad Prism software. Differences were considered significant when P < 0.05. Error bars show SD of the mean unless otherwise indicated in the figure legend. Determination of differences in vascularization in Fig. 7 , used the c 2 test on a 2 × 2 contingency table to determine two-tailed P values.
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